van der Woude H J, Bloem J L, Verstraete K L, Taminiau A H, Nooy M A, Hogendoorn P C
Department of Diagnostic Radiology, University Hospital Leiden, The Netherlands.
AJR Am J Roentgenol. 1995 Sep;165(3):593-8. doi: 10.2214/ajr.165.3.7645476.
This study analyzed the value of dynamic contrast-enhanced and subtraction MR images in detecting residual viable tumor before surgery, with emphasis on timing of enhancement, in patients with high-grade osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy.
Twenty-one patients with proved osteosarcoma or Ewing's sarcoma were treated with neoadjuvant chemotherapy followed by surgery. After IV administration of gadopentetate dimeglumine, dynamic enhancement patterns on preoperative MR images were compared with corresponding areas on histologic sections of the resected specimens. On dynamic subtraction images obtained with high temporal resolution (1.5-3 sec), the interval between arrival of the bolus of contrast agent in an artery and start of tumoral enhancement was used to distinguish residual viable tumor. Early enhancing foci (interval artery-tumor < 6 sec) and late or nonenhancing areas seen on MR images were correlated with the histopathologic findings in these areas of the resected specimens.
Early and progressively enhancing structures seen on MR images corresponded to feeding arteries, physeal vessels, or residual viable tumor at specific preferential sites on corresponding histologic sections of the resected specimens. Tumor foci as small as 3-5 mm2 could be detected on dynamic MR images. Remnant viable tumor was often located subperiosteally and at the margins of the tumor. Occasionally, active periosteal reaction without presence of viable tumor contributed to early enhancement. Late and gradually enhancing or nonenhancing areas corresponded histopathologically to regions of chemotherapy-induced necrosis, mucomyxoid degeneration, or fibrosis. Alternatively, late or nonenhancing areas were associated with reactive changes such as edema, hemorrhage, or osteomyelitis or with tumor-related extracellular matrices such as abundant osteoid or chondroid. Viable tumor areas with scarce formation of matrix on microscopy, such as small cell osteosarcoma areas or Ewing's sarcoma, showed early enhancement with rapid washout of contrast agent on the dynamic MR images.
Fast dynamic contrast-enhanced sequences are essential for identifying residual tumor before surgery. A short time interval of less than 6 sec between arterial enhancement and tumoral enhancement strongly correlates with presence of viable tumor. Both therapy-related alterations of tissue and tumor-related matrices must be considered when late or lack of enhancement is noted on dynamic MR images.
本研究分析动态对比增强及减影磁共振成像(MR)在检测新辅助化疗后高级别骨肉瘤和尤因肉瘤患者术前残余存活肿瘤中的价值,重点关注增强时机。
21例经证实的骨肉瘤或尤因肉瘤患者接受新辅助化疗后行手术治疗。静脉注射钆喷酸葡胺后,将术前MR图像上的动态增强模式与切除标本组织学切片上的相应区域进行比较。在高时间分辨率(1.5 - 3秒)获得的动态减影图像上,利用对比剂团注到达动脉与肿瘤开始增强之间的时间间隔来区分残余存活肿瘤。MR图像上早期增强灶(动脉 - 肿瘤时间间隔 < 6秒)以及晚期或无增强区域与切除标本这些区域的组织病理学结果相关。
MR图像上早期且逐渐增强的结构对应于切除标本相应组织学切片上特定优先部位的供血动脉、骨骺血管或残余存活肿瘤。在动态MR图像上可检测到小至3 - 5平方毫米的肿瘤灶。残余存活肿瘤常位于骨膜下及肿瘤边缘。偶尔,无存活肿瘤的活跃骨膜反应也会导致早期增强。晚期且逐渐增强或无增强区域在组织病理学上对应化疗诱导坏死、黏液样变性或纤维化区域。或者,晚期或无增强区域与水肿、出血或骨髓炎等反应性改变或与丰富骨样或软骨样等肿瘤相关细胞外基质有关。显微镜下基质形成稀少的存活肿瘤区域,如小细胞骨肉瘤区域或尤因肉瘤,在动态MR图像上表现为早期增强且对比剂快速廓清。
快速动态对比增强序列对于术前识别残余肿瘤至关重要。动脉增强与肿瘤增强之间短于6秒的时间间隔与存活肿瘤的存在密切相关。当动态MR图像上出现晚期或无增强时,必须考虑与治疗相关的组织改变以及肿瘤相关基质。